Get Cash Back and $0 Commissions
+ The Power of TradeStation
ACCESSWIRE 24-Jan-2023 7:44 PM
NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
AFRM Shareholders Click Here: https://www.zlk.com/pslra-1/affirm-class-action-submission-form?prid=35909&wire=1
TWST Shareholders Click Here: https://www.zlk.com/pslra-1/twist-bioscience-loss-submission-form?prid=35909&wire=1
DAKT Shareholders Click Here: https://www.zlk.com/pslra-1/daktronics-class-action-submission-form?prid=35909&wire=1
* ADDITIONAL INFORMATION BELOW *
AFRM Lawsuit on behalf of: investors who purchased February 12, 2021 - December 15, 2021
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/affirm-class-action-submission-form?prid=35909&wire=1
According to the filed complaint, during the class period, Affirm Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Affirm's "buy-now, pay-later" service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (ii) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Twist Bioscience Corporation (NASDAQ:TWST)
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive.
Lead Plaintiff Deadline : February 10, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/twist-bioscience-loss-submission-form?prid=35909&wire=1
According to the filed complaint, 1) as alleged in the November 15, 2022 report by Scorpion Capital, defendants overstated the commercial viability of Twist's synthetic DNA manufacturing technology; and 2) at the same time, defendants were engaging in accounting fraud and using unsustainable pricing to inflate the Company's true financial condition and prospects.
Daktronics, Inc. (NASDAQ:DAKT)
DAKT Lawsuit on behalf of: investors who purchased March 10, 2022 - December 6, 2022
Lead Plaintiff Deadline : February 21, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/daktronics-class-action-submission-form?prid=35909&wire=1
According to the filed complaint, during the class period, Daktronics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing challenges that increased costs, including supply chain disruptions, that impacted Daktronics' ability to fund inventory levels and operations; (2) as a result, it was probable that some portion of the Company's deferred tax assets would not be realized; (3) as a result, Daktronics was reasonably likely to record a material valuation allowance to its deferred tax assets; (4) there were material weaknesses in the Company's internal controls over financial reporting related to income taxes; (5) the foregoing presented liquidity concerns and there was substantial doubt as to the Company's ability to continue as a going concern; and (6) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP